To Örebro University

oru.seÖrebro University Publications
Change search
Link to record
Permanent link

Direct link
Sundqvist, Martin
Alternative names
Publications (10 of 47) Show all publications
Lind, A., Cao, Y., Hesser, H., Hårdstedt, M., Jansson, S. P. O., Lernmark, Å., . . . Jendle, J. (2024). Anxiety, depression and quality of life in relation to SARS-CoV-2 antibodies in individuals living with diabetes during the second wave of COVID-19. Diabetes epidemiology and management, 13, Article ID 100194.
Open this publication in new window or tab >>Anxiety, depression and quality of life in relation to SARS-CoV-2 antibodies in individuals living with diabetes during the second wave of COVID-19
Show others...
2024 (English)In: Diabetes epidemiology and management, ISSN 2666-9706, Vol. 13, article id 100194Article in journal (Refereed) Published
Abstract [en]

Aims: The objective was to compare anxiety, depression, and quality of life (QoL) in individuals living with type 1 (T1D) and type 2 (T2D) diabetes with matched controls during the second wave of the COVID-19 pandemic.

Methods: Via randomization, individuals living with diabetes T1D (n = 203) and T2D (n = 413), were identified during February-July 2021 through health-care registers. Population controls (n = 282) were matched for age, gender, and residential area. Questionnaires included self-assessment of anxiety, depression, QoL, and demographics in relation to SARS-CoV-2 exposure. Blood was collected through home-capillary sampling, and SARS-CoV-2 Nucleocapsid (NCP) and Spike antibodies (SC2_S1) were determined by multiplex Antibody Detection by Agglutination-PCR (ADAP) assays.

Results: Younger age and health issues were related to anxiety, depression, and QoL, with no differences between the study groups. Female gender was associated with anxiety, while obesity was associated with lower QoL. The SARS-CoV-2 NCP seroprevalence was higher in T1D (8.9 %) compared to T2D (3.9 %) and controls (4.0 %), while the SARS-CoV-2 SC2_S1 seroprevalence was higher for controls (25.5 %) compared to T1D (16.8 %) and T2D (14.0 %).

Conclusions: A higher SARS-CoV-2 infection rate in T1D may be explained by younger age and higher employment rate, and the associated increased risk for viral exposure.

Place, publisher, year, edition, pages
Elsevier, 2024
Keywords
Diabetes, SARS-CoV-2, COVID-19, Anxiety, Depression, Quality of life, Virus antibodies
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:oru:diva-111559 (URN)10.1016/j.deman.2023.100194 (DOI)001154927400001 ()2-s2.0-85182889973 (Scopus ID)
Funder
Swedish Foundation for Strategic Research, IRC15-0067
Note

This work was supported by NIH SBIR 2R44DK110005-02, Strategic Research Area Exodiab Dnr 2009-1039, and the Swedish Foundation for Strategic Research Dnr IRC15-0067.

Available from: 2024-02-14 Created: 2024-02-14 Last updated: 2024-02-14Bibliographically approved
Pallon, J., Sundqvist, M. & Hedin, K. (2024). The use and usefulness of point-of-care tests in patients with pharyngotonsillitis - an observational study in primary health care. BMC primary care, 25(1), Article ID 15.
Open this publication in new window or tab >>The use and usefulness of point-of-care tests in patients with pharyngotonsillitis - an observational study in primary health care
2024 (English)In: BMC primary care, E-ISSN 2731-4553, Vol. 25, no 1, article id 15Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Rapid antigen detection tests (RADT) for Group A streptococci (GAS) and point-of-care tests for C-reactive protein (CRP) are commonly used in patients with pharyngotonsillitis in Sweden and Denmark although CRP testing is not supported by guidelines. We aimed to describe (1) the proportion of patients tested with RADT and/or CRP, (2) the relation between test results and antibiotic prescribing, and (3) the association between CRP level and microbial aetiology.

METHODS: We used a post-hoc-analysis of data collected in primary health care in a prospective aetiological study of 220 patients 15-45 years old diagnosed with pharyngotonsillitis. The outcomes of RADTs and CRP tests were related to antibiotic prescribing and microbial aetiology.

RESULTS: A RADT was used in 94% of the patients. A CRP test was used in 50% of the patients but more commonly in those with a negative RADT (59%) than in those with a positive RADT (38%) (p = 0.005). Most (74%) CRP tests were used in patients with a negative RADT. Antibiotic prescribing differed greatly between patients with a positive RADT (96%) and patients with a negative RADT (17%) (p < 0.001). In patients with a negative RADT, there was a positive association between CRP value and antibiotic prescribing (OR 1.05; 95% CI 1.02-1.07; p < 0.001). Patients with CRP values ≤ 30 mg/l were seldomly prescribed antibiotics. Patients with GAS in culture had the highest median CRP (46 mg/l), which was higher than in patients without GAS (8 mg/l; p < 0.001). However, the positive predictive value for GAS never exceeded 0.60 (95% CI 0.31-0.83) at the investigated CRP levels.

CONCLUSIONS: The widespread use of tests is a major deviation from national guidelines. Most CRP tests were used in patients with a negative RADT, suggesting a belief in the added value of a CRP test, and the CRP result seemed to influence antibiotic prescribing. However, as an aetiological test, CRP is not useful for predicting GAS.

Place, publisher, year, edition, pages
BioMed Central (BMC), 2024
Keywords
Aetiology, Antibiotic prescribing, C-reactive protein, Pharyngotonsillitis, Primary health care, Rapid antigen detection test
National Category
Infectious Medicine
Identifiers
urn:nbn:se:oru:diva-110621 (URN)10.1186/s12875-023-02245-9 (DOI)001137223400001 ()38184547 (PubMedID)2-s2.0-85181452078 (Scopus ID)
Funder
Lund UniversityRegion Kronoberg
Available from: 2024-01-09 Created: 2024-01-09 Last updated: 2024-02-01Bibliographically approved
Koskela, A., Lindqvist, C. M., Asghar, N., Johansson, M., Sundqvist, M., Mölling, P. & Stenmark, B. (2023). Comparison of SARS-CoV-2 whole genome sequencing using tiled amplicon enrichment and bait hybridization. In: : . Paper presented at Smögen Virology Symposium 2023, Smögen, Sweden, August 24-26, 2023..
Open this publication in new window or tab >>Comparison of SARS-CoV-2 whole genome sequencing using tiled amplicon enrichment and bait hybridization
Show others...
2023 (English)Conference paper, Poster (with or without abstract) (Other academic)
Abstract [en]

The severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) worldwide pandemic has led to extensive virological monitoring by whole genome sequencing (WGS). Investigating the advantages and limitations of different protocols is key when conducting population-level WGS. SARS-CoV-2 positive samples with Ct values of 14–30 were run using three different protocols: the Twist Bioscience SARS‑CoV‑2 protocol with bait hybridization enrichment sequenced with Illumina, and two tiled amplicon enrichment protocols, ARTIC V3 and Midnight, sequenced with Illumina and Oxford Nanopore Technologies, respectively. Twist resulted in better coverage uniformity and coverage of the entire genome, but has several drawbacks: high human contamination, laborious workflow, high cost, and variation between batches. The ARTIC and Midnight protocol produced an even coverage across samples, and almost all reads were mapped to the SARS-CoV-2 reference. ARTIC and Midnight represent robust, cost-effective, and highly scalable methods that are appropriate in a clinical environment. Lineage designations were uniform across methods, representing the dominant lineages in Sweden during the period of collection. This study provides insights into methodological differences in SARS‑CoV‑2 sequencing and guidance in selecting suitable methods for various purposes.

National Category
Infectious Medicine
Identifiers
urn:nbn:se:oru:diva-108004 (URN)
Conference
Smögen Virology Symposium 2023, Smögen, Sweden, August 24-26, 2023.
Available from: 2023-09-01 Created: 2023-09-01 Last updated: 2023-09-05Bibliographically approved
Koskela, A., Lindqvist, C. M., Asghar, N., Johansson, M., Sundqvist, M., Mölling, P. & Stenmark, B. (2023). Comparison of SARS-CoV-2 whole genome sequencing using tiled amplicon enrichment and bait hybridization. Scientific Reports, 13(1), Article ID 6461.
Open this publication in new window or tab >>Comparison of SARS-CoV-2 whole genome sequencing using tiled amplicon enrichment and bait hybridization
Show others...
2023 (English)In: Scientific Reports, E-ISSN 2045-2322, Vol. 13, no 1, article id 6461Article in journal (Refereed) Published
Abstract [en]

The severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) pandemic has led to extensive virological monitoring by whole genome sequencing (WGS). Investigating the advantages and limitations of different protocols is key when conducting population-level WGS. SARS-CoV-2 positive samples with Ct values of 14-30 were run using three different protocols: the Twist Bioscience SARS‑CoV‑2 protocol with bait hybridization enrichment sequenced with Illumina, and two tiled amplicon enrichment protocols, ARTIC V3 and Midnight, sequenced with Illumina and Oxford Nanopore Technologies, respectively. Twist resulted in better coverage uniformity and coverage of the entire genome, but has several drawbacks: high human contamination, laborious workflow, high cost, and variation between batches. The ARTIC and Midnight protocol produced an even coverage across samples, and almost all reads were mapped to the SARS-CoV-2 reference. ARTIC and Midnight represent robust, cost-effective, and highly scalable methods that are appropriate in a clinical environment. Lineage designations were uniform across methods, representing the dominant lineages in Sweden during the period of collection. This study provides insights into methodological differences in SARS‑CoV‑2 sequencing and guidance in selecting suitable methods for various purposes.

Place, publisher, year, edition, pages
Springer Nature, 2023
National Category
Infectious Medicine
Identifiers
urn:nbn:se:oru:diva-105616 (URN)10.1038/s41598-023-33168-1 (DOI)001025198300001 ()37081087 (PubMedID)2-s2.0-85153442204 (Scopus ID)
Funder
Region Örebro CountyÖrebro University
Available from: 2023-04-21 Created: 2023-04-21 Last updated: 2023-09-05Bibliographically approved
Andreasson, A., Hällgren, A., Georgeoulas, P., Forsberg, J., Fridriksson, J., Granåsen, G., . . . Styrke, J. (2023). Fosfomycin versus Ciprofloxacin as transrectal prostatebiopsy antibiotic prophylaxis an open randomized controlled multicenter drug trial. Paper presented at 38th Annual EAU Congress, Milan, Italy, March 10-13, 2023. European Urology, 83(Suppl. 1), S180-S180, Article ID A0131.
Open this publication in new window or tab >>Fosfomycin versus Ciprofloxacin as transrectal prostatebiopsy antibiotic prophylaxis an open randomized controlled multicenter drug trial
Show others...
2023 (English)In: European Urology, ISSN 0302-2838, E-ISSN 1873-7560, Vol. 83, no Suppl. 1, p. S180-S180, article id A0131Article in journal, Meeting abstract (Other academic) Published
Abstract [en]

Introduction & Objectives: Antibiotic prophylaxis are administered as a routine to decrease the risk for septic complications following transrectal prostate biopsy. Fosfomycin administered 1 h or more prior to biopsy has equal or better infectious complication rates as compared to Ciprofloxacin in both prospective and retrospective studies from countries with high rates of antibiotic resistance. The aim of this study was to investigate if Fosfomycin administered immediately prior to prostate biopsy was as effective as Ciprofloxacin in Sweden, a country with low rates of antibiotic resistance.

Materials & Methods: A randomized, controlled, open, multicenter, non-inferiority-study including men of all ages undergoing transrectal prostate biopsy was performed in the urology departments of three Swedish hospitals. The total number of patients were planned for 3448, divided into low and high infection risk groups. The low-risk group was randomized to either one dose of Fosfomycin 3g or Ciprofloxacin 750mg before biopsy. The high-risk group was randomized to either two doses of Fosfomycin 3g prior to biopsy and one more 24 h after biopsy or Ciprofloxacin 500mg once prior to biopsy and then twice daily for three days. The drugs were administered orally. All patients had a rectal swab for culture before and after biopsy. The endpoint was hospitalisation due to urinary tract infection within 14 days from biopsy, follow-up was performed with a phone interview.

Results: The safety board prematurely interrupted the study after 42 included patients due to an unusual high number of hospitalisations. Four out of 20 patients (20%), three in the low-risk group and one in the high-risk group, had been hospitalised due to urosepsis in the Fosfomycin group. One further patient described fever symptoms but did not seek health care. No patient in the Ciprofloxacin group (n=21) described symptoms of infection from the urinary tract. One patient was lost to follow-up. A one-sided binomial test showed a p-value of <0.001. Two of the four hospitalised patients had a positive blood culture for Pseudomonas Aeruginosa and one had a positive rectal swab culture for Pseudomonas species both before and after biopsy.

Conclusions: The study does not support the use of Fosfomycin administered immediately prior to prostate biopsy. The results may have been affected by the unexpected high number of Pseudomonas infections, a bacteria where Fosfomycin often lack effect. If Fosfomycin is to be used it should be with caution if Pseudomonas has been seen in earlier cultures

Place, publisher, year, edition, pages
Elsevier, 2023
National Category
Urology and Nephrology
Identifiers
urn:nbn:se:oru:diva-106325 (URN)000991496000125 ()
Conference
38th Annual EAU Congress, Milan, Italy, March 10-13, 2023
Available from: 2023-06-19 Created: 2023-06-19 Last updated: 2023-06-19Bibliographically approved
Göransson, J., Sundqvist, M., Ghaderi, E., Lisby, J. G., Molin, Y., Eriksson, E., . . . Melin, J. (2023). Performance of a System for Rapid Phenotypic Antimicrobial Susceptibility Testing of Gram-Negative Bacteria Directly from Positive Blood Culture Bottles. Journal of Clinical Microbiology, 61(3), Article ID e0152522.
Open this publication in new window or tab >>Performance of a System for Rapid Phenotypic Antimicrobial Susceptibility Testing of Gram-Negative Bacteria Directly from Positive Blood Culture Bottles
Show others...
2023 (English)In: Journal of Clinical Microbiology, ISSN 0095-1137, E-ISSN 1098-660X, Vol. 61, no 3, article id e0152522Article in journal (Refereed) Published
Abstract [en]

The rapid administration of optimal antimicrobial treatment is paramount for the treatment of bloodstream infections (BSIs), and rapid antimicrobial susceptibility testing (AST) results are essential. Q-linea has developed the ASTar system, a rapid phenotypic AST device. Here, we report the performance of the ASTar BC G- (Gram-negative) kit when assessed according to the ISO 20776-2:2007 standard for performance evaluation of in vitro diagnostic AST devices. The evaluated ASTar BC G- kit uses a broad panel of 23 antimicrobials for the treatment of BSIs caused by Gram-negative fastidious and nonfastidious bacteria across a range of 6 to 14 2-fold dilutions, including cefoxitin as a screening agent for AmpC-producing Enterobacterales. The ASTar system processes blood culture samples to generate data on MICs and susceptible, intermediate, or resistant (SIR) category. The automated protocol includes concentration determination and concentration adjustment to enable a controlled inoculum, followed by broth microdilution (BMD) and microscopy performed continuously to generate MIC values within approximately 6 h once the test is run on the ASTar system. The performance of the ASTar system was assessed against the ISO 20776-2:2007 standard BMD reference method. Testing was performed across three sites, with results from 412 contrived blood cultures and 74 fresh clinical blood cultures. The ASTar system was also tested for reproducibility, with triplicate testing of 11 strains. The accuracy study comprised 8,650 data points of bacterium-antimicrobial tests. The ASTar system demonstrated an overall essential agreement (EA) of 95.8% (8,283/8,650) and a categorical agreement (CA) of 97.6% (8,433/8,639) compared to the reference BMD method. The overall rate of major discrepancies (MDs) was 0.9% (62/6,845), and that of very major discrepancies (VMDs) was 2.4% (30/1,239). This study shows that the ASTar system delivers reproducible results with overall EA and CA of >95%.

Place, publisher, year, edition, pages
American Society for Microbiology, 2023
Keywords
MIC, antimicrobial susceptibility testing, phenotypic AST, rapid AST
National Category
Infectious Medicine
Identifiers
urn:nbn:se:oru:diva-104579 (URN)10.1128/jcm.01525-22 (DOI)000940684300001 ()36852983 (PubMedID)2-s2.0-85151043232 (Scopus ID)
Available from: 2023-03-01 Created: 2023-03-01 Last updated: 2023-05-19Bibliographically approved
Säll, O., Eriksson, L., Idosa Berhane, A., Persson, A., Magnuson, A., Thulin Hedberg, S., . . . Jacobsson, S. (2023). Prevalence and persistence of Neisseria meningitidis carriage in Swedish university students. Epidemiology and Infection, 151, Article ID e25.
Open this publication in new window or tab >>Prevalence and persistence of Neisseria meningitidis carriage in Swedish university students
Show others...
2023 (English)In: Epidemiology and Infection, ISSN 0950-2688, E-ISSN 1469-4409, Vol. 151, article id e25Article in journal (Refereed) Published
Abstract [en]

The bacterium Neisseria meningitidis causes life-threatening disease worldwide, typically with a clinical presentation of sepsis or meningitis, but can be carried asymptomatically as part of the normal human oropharyngeal microbiota. The aim of this study was to examine N. meningitidis carriage with regard to prevalence, risk factors for carriage, distribution of meningococcal lineages and persistence of meningococcal carriage. Throat samples and data from a self-reported questionnaire were obtained from 2744 university students (median age: 23 years) at a university in Sweden on four occasions during a 12-month period. Meningococcal isolates were characterised using whole-genome sequencing. The carriage rate among the students was 9.1% (319/3488; 95% CI 8.2-10.1). Factors associated with higher carriage rate were age ≤22 years, previous tonsillectomy, cigarette smoking, drinking alcohol and attending parties, pubs and clubs. Female gender and sharing a household with children aged 0-9 years were associated with lower carriage. The most frequent genogroups were capsule null locus (cnl), group B and group Y and the most commonly identified clonal complexes (cc) were cc198 and cc23. Persistent carriage with the same meningococcal strain for 12 months was observed in two students. Follow-up times exceeding 12 months are recommended for future studies investigating long-term carriage of N. meningitidis.

Place, publisher, year, edition, pages
Cambridge University Press, 2023
Keywords
Carriage, Neisseria meningitidis, Swedish snus, university students, whole genome sequencing
National Category
Public Health, Global Health, Social Medicine and Epidemiology
Identifiers
urn:nbn:se:oru:diva-104135 (URN)10.1017/S0950268823000018 (DOI)000930011500001 ()36775828 (PubMedID)2-s2.0-85147835011 (Scopus ID)
Available from: 2023-02-13 Created: 2023-02-13 Last updated: 2023-03-16Bibliographically approved
Haars, J., Palanisamy, N., Wallin, F., Mölling, P., Lindh, J., Sundqvist, M., . . . Lennerstrand, J. (2023). Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022-2023. Microorganisms, 11(10), Article ID 2417.
Open this publication in new window or tab >>Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022-2023
Show others...
2023 (English)In: Microorganisms, E-ISSN 2076-2607, Vol. 11, no 10, article id 2417Article in journal (Refereed) Published
Abstract [en]

Monoclonal antibodies (mAbs) are an important treatment option for COVID-19 caused by SARS-CoV-2, especially in immunosuppressed patients. However, this treatment option can become ineffective due to mutations in the SARS-CoV-2 genome, mainly in the receptor binding domain (RBD) of the spike (S) protein. In the present study, 7950 SARS-CoV-2 positive samples from the Uppsala and Örebro regions of central Sweden, collected between March 2022 and May 2023, were whole-genome sequenced using amplicon-based sequencing methods on Oxford Nanopore GridION, Illumina MiSeq, Illumina HiSeq, or MGI DNBSEQ-G400 instruments. Pango lineages were determined and all single nucleotide polymorphism (SNP) mutations that occurred in these samples were identified. We found that the dominant sublineages changed over time, and mutations conferring resistance to currently available mAbs became common. Notable ones are R346T and K444T mutations in the RBD that confer significant resistance against tixagevimab and cilgavimab mAbs. Further, mutations conferring a high-fold resistance to bebtelovimab, such as the K444T and V445P mutations, were also observed in the samples. This study highlights that resistance mutations have over time rendered currently available mAbs ineffective against SARS-CoV-2 in most patients. Therefore, there is a need for continued surveillance of resistance mutations and the development of new mAbs that target more conserved regions of the RBD.

Place, publisher, year, edition, pages
MDPI, 2023
Keywords
SARS-CoV-2, Sweden, coronavirus, monoclonal antibodies, nanopore, receptor binding domain, resistance, whole-genome sequencing
National Category
Infectious Medicine
Identifiers
urn:nbn:se:oru:diva-109496 (URN)10.3390/microorganisms11102417 (DOI)001089500500001 ()37894075 (PubMedID)2-s2.0-85175035325 (Scopus ID)
Funder
Sjukvårdsregionala forskningsrådet Mellansverige, RFR-980115
Available from: 2023-10-31 Created: 2023-10-31 Last updated: 2023-12-08Bibliographically approved
Åkerlund, A., Serrander, L. & Sundqvist, M. (2023). Short incubation of disc diffusion for Streptococcus pneumoniae and Haemophilus influenzae to reduce time to susceptibility report. Journal of Antimicrobial Chemotherapy, 78(10), 2563-2571
Open this publication in new window or tab >>Short incubation of disc diffusion for Streptococcus pneumoniae and Haemophilus influenzae to reduce time to susceptibility report
2023 (English)In: Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, E-ISSN 1460-2091, Vol. 78, no 10, p. 2563-2571Article in journal (Refereed) Published
Abstract [en]

Background: Rapidly instituted antimicrobial therapy is important in severe infections, and reduced time to the antimicrobial susceptibility testing (AST) report is thus of importance. Disc diffusion (DD) is a cheap, rapidly adaptable, flexible and comprehensive method for phenotypic AST. Previous studies have shown that early reading of inhibition zones for non-fastidious species is possible.

Objectives: To evaluate zone reading after short incubation of DD in Haemophilus influenzae (n = 73) and Streptococcus pneumoniae (n = 112).

Methods: The readability was evaluated and susceptibility interpretation (SIR) was performed, using the EUCAST 18 & PLUSMN; 2 h incubation breakpoint table (version 12.0), after 6 and 8 h of incubation. Categorical agreement (CA) and error rates were calculated using standard DD and broth microdilution as reference.

Results: The proportion of readable zones in H. influenzae was 19% (6 h) and 89% (8 h). The CA was 98% after 8 h. The corresponding readability in S. pneumoniae was 63%/98% and CA was 95%/97% after 6 and 8 h, respectively. Early reading of the screening discs (benzylpenicillin 1 unit in H. influenzae and oxacillin 1 & mu;g in S. pneumoniae) correctly identified 18/22 of the H. influenzae isolates and all the readable S. pneumoniae isolates with reduced & beta;-lactam susceptibility. For non-& beta;-lactam agents, very major errors were most common for quinolones in S. pneumoniae. Introduction of areas of technical uncertainty (ATUs) reduced the error rate to & LE;1.1%.

Conclusions: We conclude that shortened incubation is feasible for H. influenzae and S. pneumoniae. To reduce the risk of false categorization a buffer zone (i.e. ATU) near the breakpoints must be used.

Place, publisher, year, edition, pages
Oxford University Press, 2023
National Category
Infectious Medicine
Identifiers
urn:nbn:se:oru:diva-108297 (URN)10.1093/jac/dkad272 (DOI)001058258900001 ()37667593 (PubMedID)2-s2.0-85174080379 (Scopus ID)
Available from: 2023-09-15 Created: 2023-09-15 Last updated: 2023-12-08Bibliographically approved
Haglund, S., Lager, M., Gyllemark, P., Andersson, G., Ekelund, O., Sundqvist, M. & Henningsson, A. J. (2022). CXCL13 in laboratory diagnosis of Lyme neuroborreliosis-the performance of the recomBead and ReaScan CXCL13 assays in human cerebrospinal fluid samples. European Journal of Clinical Microbiology and Infectious Diseases, 41(1), 175-179
Open this publication in new window or tab >>CXCL13 in laboratory diagnosis of Lyme neuroborreliosis-the performance of the recomBead and ReaScan CXCL13 assays in human cerebrospinal fluid samples
Show others...
2022 (English)In: European Journal of Clinical Microbiology and Infectious Diseases, ISSN 0934-9723, E-ISSN 1435-4373, Vol. 41, no 1, p. 175-179Article in journal (Refereed) Published
Abstract [en]

The chemokine CXCL13 is used as complement to serology in the diagnostics of Lyme neuroborreliosis (LNB). We evaluated and compared the semi-quantitative, cassette-based ReaScan CXCL13 assay with the quantitative recomBead CXCL13 assay using a collection of 209 cerebrospinal fluid samples. The categorical agreement between results interpreted as negative, grey zone, and positive by the two methods was 87%. The diagnostic sensitivity was higher using the recomBead assay, whereas specificity was higher using ReaScan. Few manual steps, and a short turn-around time with no batching of samples makes the ReaScan CXCL13 assay an attractive complement to serology in the diagnostics of LNB.

Place, publisher, year, edition, pages
Springer, 2022
Keywords
CXCL13, Diagnostics, Lyme neuroborreliosis, ReaScan, recomBead
National Category
Infectious Medicine
Identifiers
urn:nbn:se:oru:diva-94879 (URN)10.1007/s10096-021-04350-y (DOI)000705823200001 ()34626256 (PubMedID)2-s2.0-85116568394 (Scopus ID)
Funder
European Commission
Note

Funding agency:

Interreg North Sea Region Programme J-No: 38-2-7-19 

Available from: 2021-10-11 Created: 2021-10-11 Last updated: 2023-12-08Bibliographically approved
Organisations

Search in DiVA

Show all publications